QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IMNM

QT61Immunome, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
18.74
+0.21+1.13%
OverviewShort InterestFilings
IMNMQT61Immunome, Inc.·NASDAQ
OverviewShort InterestFilings
18.74+1.13%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.08
Insider Own7.28%
Shs Outstand113.25M
Perf Week2.07%
Market Cap1.77BForward P/E-EPS next Y-2.14Insider Trans-0.23%Shs Float-Perf Month-4.68%
Enterprise Value1.19BPEG-EPS next Q-0.54Inst Own-Short Float-Perf Quarter-10.03%
Income-189714772.00P/S441.19EPS this Y30.44%Inst Trans-Short Ratio-Perf Half Y-20.19%
Sales4.01MP/B3.56EPS next Y0.34%ROA-36.24%Short Interest-Perf YTD-12.76%
Book/sh5.20P/C-EPS next 5Y-ROE-51.15%52W High27.65 -32.22%Perf Year109.39%
Cash/sh5.15P/FCF-EPS past 3/5Y-ROIC-40.31%52W Low7.96 135.43%Perf 3Y-
Dividend Est.-EV/EBITDA-5.38Sales past 3/5Y-Gross Margin-1161.92%Volatility2.99% 3.56%Perf 5Y-
Dividend TTM-EV/Sales296.98EPS Y/Y TTM52.40%Oper. Margin-5947.90%ATR (14)1.00Perf 10Y-
Dividend Ex-Date-Quick Ratio21.68Sales Y/Y TTM44.44%Profit Margin-5593.85%RSI (14)40.61Recom2.00
Dividend Gr. 3/5Y-Current Ratio21.68EPS Q/Q7.69%SMA20-5.44%Beta1.84Target Price36.50
Payout0.00%Debt/Eq0.01Sales Q/Q-100.00%SMA50-13.06%Rel Volume2.96Prev Close18.53
Employees131LT Debt/Eq0.01EarningsAug 05SMA200-3.10%Avg Volume1.12MPrice18.74
IPO DateOct 02, 2020Option/ShortYes / YesEPS/Sales Surpr.20.00% -Net Debt/EBITDA2.61Volume3,318,515Change1.13%
Analyst Ratings
DateActionAnalystRatingTarget
May-28-26ReiteratedTruist Financial$36 → $37
May-28-26ReiteratedBarclays$36
May-15-26ReiteratedLeerink PartnersOutperform$40 → $33
Feb-12-26InitiatedH.CBuy$40
Dec-16-25ReiteratedEvercore ISI$18 → $40
Dec-16-25ReiteratedLake StreetBuy$32
Dec-15-25ReiteratedLeerink Partners$38 → $40
Dec-01-25InitiatedTruistBuy$36
Nov-17-25ReiteratedStephens$33
Sep-05-25InitiatedCraig-HallumBuy$26
Latest News
Jun-12-26
Jun-12-2610:04AM
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price TargetBenzinga
Jun-11-26
Jun-11-2607:32AM
Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid TumorsBenzinga
07:32AM
Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid TumorsBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1379
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A130
Gross Profit1249
Selling, General and Administrative Excl. Other414433
Research and Development162174130
Other Operating Expense340152
Operating Income-225-214-306
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-40-2-152
Net Income Before Taxes-212-212-293
Income Taxes
000
Consolidated Net Income-212-212-293
Net Income From Continuing Operations-212-212-293
Net Income-212-212-293
EPS (Recurring)-3.08-2.43-5.00
EPS (Basic, Before Extraordinaries)-3.08-2.43-5.00
EPS (Diluted)-3.08-2.43-5.00
EBITDA-182-209-151
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio125.41266.97—
Gross Margin92.3157.14100.00
Operating Margin-1,730.77-3,057.14-3,400.00
Net Margin-1,630.77-3,028.57-3,255.56
Shares Outstanding878759
Market Capitalization1,6301,869—
Operating Lease Expense
———
Insider Trading Volume
$22.45$19.61$16.77$13.92$11.08● Close Price0.00M2.08M4.17M6.25M8.33MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rosett MaxChief Financial OfficerJun 15 '26Option Exercise1.05120,000126,000114,037Jun 17 12:00 AM
Rosett MaxChief Financial OfficerJun 15 '26Sale18.2360,0001,093,80054,037Jun 17 12:00 AM
BIENAIME JEAN JACQUESDirectorJun 05 '26Buy19.4510,500204,26043,415Jun 09 12:00 AM
BIENAIME JEAN JACQUESDirectorJun 05 '26Sale19.4110,500203,82032,915Jun 09 12:00 AM
BIENAIME JEAN JACQUESDirectorMay 15 '26Buy20.705,000103,50043,415May 19 12:00 AM
Higgins JackChief Scientific OfficerApr 02 '26Sale21.649,438204,23822,000Apr 03 12:00 AM
Rosett MaxChief Financial OfficerApr 02 '26Option Exercise1.22143,122174,106119,037Apr 03 12:00 AM
Rosett MaxChief Financial OfficerApr 02 '26Sale21.9265,0001,424,91654,037Apr 03 12:00 AM
SIEGALL CLAY BPresident and CEOMar 27 '26Buy19.6725,450500,602690,704Mar 31 12:00 AM
WAGENHEIM PHILIPDirectorMar 23 '26Sale20.6528,200582,330341,147Mar 23 12:00 AM
WAGENHEIM PHILIPDirectorMar 20 '26Sale20.4736,800753,296369,347Mar 23 12:00 AM
BIENAIME JEAN JACQUESDirectorMar 11 '26Buy21.551,00021,55038,415Mar 12 12:00 AM
BIENAIME JEAN JACQUESDirectorMar 10 '26Buy22.121,00022,12037,415Mar 12 12:00 AM
SIEGALL CLAY BPresident and CEODec 30 '25Buy21.154,729100,018665,254Dec 30 12:00 AM
Barchas IsaacDirectorDec 22 '25Sale21.74383,2008,330,0792,031,181Dec 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR